Why is this study important?
- Assesses the results of ticagrelor monotherapy at one year, after three months of initial DAPT (dual antiplatelet therapy) in high-risk PCI (percutaneous coronary intervention) patients
What question was this study supposed to answer?
- Is ticagrelor monotherapy vs. DAPT sufficient to reduce repeat revascularization (the primary endpoint), with PCI or CABG (coronary artery bypass grafting) for recurrent or persistent symptomatic ischemia
- Secondary endpoints were also reported
What did the study show?
- Post hoc analysis of 6,759 patients in the TWILIGHT trial
- High risk PCI patients were enrolled
- Ticagrelor monotherapy with initial 3 month of DAPT (Aspirin and Ticagrelor) was associated with:
- Similar rates of repeat revascularization (7.1% vs 6.7%, HR 1.07, 95% CI 0.89-1.29)-the primary end point
- Secondary endpoints demonstrated similar rates of:
- Major adverse cardiac and cerebrovascular events (MACCE)
- Target lesion revascularization (TLR)
- Target vessel revascularization (TVR)
- A benefit was seen in:
- Effective reduction of BARC, 2,3,5 bleeding
- Net adverse cardiac events (NACE)
Conclusion:
In high-risk PCI patients, Ticagrelor monotherapy after three months of initial DAPT, demonstrates safety without increased risk of repeat revascularization at 12 months.
Integrated Search Topics